AGM/EGMApr 28, 2026, 04:39 PM
BIIB 2026 AGM on June 9; Maria Freire to Chair Board; 2025 Growth Rev +19%
AI Summary
Biogen Inc. filed its definitive proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 9, 2026. The meeting will include the election of 10 director nominees, ratification of PricewaterhouseCoopers LLP as independent auditor, and an advisory vote on executive compensation. Caroline Dorsa will conclude her service as Board Chair, with Dr. Maria C. Freire becoming the incoming Chair. The company highlighted strong 2025 financial performance, including a 19% increase in growth product revenue to $3.3 billion, pipeline advancements, and $800 million in net operating expense savings from its Fit for Growth initiative. Biogen also mentioned its early 2026 merger agreement with Apellis Pharmaceuticals.
Key Highlights
- 2026 Annual Meeting of Stockholders scheduled for Tuesday, June 9, 2026.
- Caroline Dorsa to conclude service as Board Chair; Dr. Maria C. Freire named incoming Chair.
- Stockholders to vote on election of 10 director nominees and auditor ratification.
- 2025 growth product revenue increased 19% year-over-year to $3.3 billion.
- Fit for Growth initiative delivered $800 million in net operating expense savings.
- Advancing 10 Phase 3 trials, with potential for up to five new product launches.
- Entered merger agreement with Apellis Pharmaceuticals, Inc. in early 2026.
- Executive compensation changes include new pipeline metric and increased rTSR target.